Knowledge of the molecular complexity of cancers and the role of oncogenic drivers such as mutations in genes encoding the Epidermal Growth Factor Receptor (EGFR) has flourished in the era of targeted therapies.1, 2 Molecular profiling of a cancer patient's tumor to reveal targetable alterations is an important first step in the personalization of cancer treatment plans. Here, EGFR is linked to cancer.